We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
- Authors
Arnold, Tobias; Michlmayr, Anna; Baumann, Suzann; Burghuber, Christopher; Pluschnig, Ursula; Bartsch, Rupert; Steger, Guenther; Gnant, Michael; Bergmann, Michael; Bachleitner‐Hofmann, Thomas; Oehler, Rudolf
- Abstract
Background The response of breast cancer patients to neoadjuvant chemotherapy ( NCT) is highly heterogeneous, and reliable predictive instruments remain to be defined. High-mobility group box-1 ( HMGB-1) protein is a cell death marker, which is easily detectable in plasma. We hypothesized that the initial dose of NCT with epirubicin/docetaxel induces changes in plasma HMGB-1 which could allow for an early prediction of response to therapy. Materials and methods First, we analysed whether epirubicin/docetaxel releases HMGB-1 from HCC1143 breast cancer cells in vitro. Thereafter, plasma HMGB-1 levels before and 1-4 days after the first dose of epirubicin/docetaxel-based NCT were determined in 41 breast cancer patients and correlated with pathological response to treatment. Results Treatment of HCC1143 cells with epirubicin/docetaxel resulted in a significant HMGB-1 release in vitro. In vivo, HMGB-1 levels increased significantly only in responders (pathological complete response or partial remission, n = 22) but not in nonresponders (stable or progressive disease, n = 19). Conclusion Our data suggest that early dynamic changes of plasma HMGB1 could be a promising biomarker to predict the final response to NCT in breast cancer patients.
- Subjects
BREAST cancer patients; DRUG therapy; EPIRUBICIN; DOCETAXEL; HIGH mobility group proteins; CELL death; BIOMARKERS
- Publication
European Journal of Clinical Investigation, 2013, Vol 43, Issue 3, p286
- ISSN
0014-2972
- Publication type
Article
- DOI
10.1111/eci.12043